carfilzomib + lenalidomide + dexamethasone + belantamab mafodotin

This is a four-drug combination regimen used in the treatment of multiple myeloma, particularly in relapsed or refractory cases and in clinical trials for newly diagnosed patients. The regimen includes: *Carfilzomib*: A small molecule proteasome inhibitor that irreversibly binds to the 20S proteasome, leading to cell cycle arrest and apoptosis of cancer cells[6][7]. *Lenalidomide*: An immunomodulatory agent that enhances immune response against myeloma cells and has antiangiogenic properties. *Dexamethasone*: A synthetic glucocorticoid corticosteroid with anti-inflammatory and antitumor effects. *Belantamab mafodotin (belamaf/GSK2857916)*: An antibody-drug conjugate targeting B-cell maturation antigen (BCMA) on myeloma cells; after binding BCMA, it is internalized, releasing the cytotoxic agent monomethyl auristatin F (mafodotin), which disrupts microtubules causing cell death[5]. This combination is being studied for its synergistic activity and manageable toxicity profile in multiple myeloma patients not eligible for transplant as well as those with relapsed/refractory disease[1][3][4][8].

Other names

belamaf